These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Detection of multiple types of cancer driver mutations using targeted RNA sequencing in non-small cell lung cancer. Ju S; Cui Z; Hong Y; Wang X; Mu W; Xie Z; Zeng X; Su L; Lin X; Zhang Z; Zhang Q; Song X; You S; Chen R; Chen W; Xu C; Zhao J Cancer; 2023 Aug; 129(15):2422-2430. PubMed ID: 37096747 [TBL] [Abstract][Full Text] [Related]
3. Indel sensitive and comprehensive variant/mutation detection from RNA sequencing data for precision medicine. Prodduturi N; Bhagwate A; Kocher JA; Sun Z BMC Med Genomics; 2018 Sep; 11(Suppl 3):67. PubMed ID: 30255803 [TBL] [Abstract][Full Text] [Related]
4. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. Volckmar AL; Leichsenring J; Kirchner M; Christopoulos P; Neumann O; Budczies J; Morais de Oliveira CM; Rempel E; Buchhalter I; Brandt R; Allgäuer M; Talla SB; von Winterfeld M; Herpel E; Goeppert B; Lier A; Winter H; Brummer T; Fröhling S; Faehling M; Fischer JR; Heußel CP; Herth F; Lasitschka F; Schirmacher P; Thomas M; Endris V; Penzel R; Stenzinger A Int J Cancer; 2019 Aug; 145(3):649-661. PubMed ID: 30653256 [TBL] [Abstract][Full Text] [Related]
5. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042 [TBL] [Abstract][Full Text] [Related]
6. The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable Szpechcinski A; Moes-Sosnowska J; Skronska P; Lechowicz U; Pelc M; Szolkowska M; Rudzinski P; Wojda E; Maszkowska-Kopij K; Langfort R; Orlowski T; Sliwinski P; Polaczek M; Chorostowska-Wynimko J Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063150 [TBL] [Abstract][Full Text] [Related]
7. Analytical and clinical validation of a NGS panel in detecting targetable variants from ctDNA of metastatic NSCLC patients. Fan F; Jiang G; Lv J; Wang H; Li W; Liu C; Zhao Y; Zhang Z; Du H; Zhang Z; Li X; Li WC Cancer Med; 2024 Oct; 13(19):e70078. PubMed ID: 39385536 [TBL] [Abstract][Full Text] [Related]
8. Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients. Descarpentries C; Leprêtre F; Escande F; Kherrouche Z; Figeac M; Sebda S; Baldacci S; Grégoire V; Jamme P; Copin MC; Tulasne D; Cortot AB J Thorac Oncol; 2018 Dec; 13(12):1873-1883. PubMed ID: 30195702 [TBL] [Abstract][Full Text] [Related]
9. Indel detection from RNA-seq data: tool evaluation and strategies for accurate detection of actionable mutations. Sun Z; Bhagwate A; Prodduturi N; Yang P; Kocher JA Brief Bioinform; 2017 Nov; 18(6):973-983. PubMed ID: 27473065 [TBL] [Abstract][Full Text] [Related]
10. Validation of a DNA-Based Next-Generation Sequencing Test for Molecular Diagnostic Variant and Fusion Detection in Formalin-Fixed, Paraffin-Embedded Tissue Specimens and Liquid Biopsy Plasma/Cell-Free DNA Samples. Werner TV; Kock S; Weber I; Kayser G; Werner M; Lassmann S J Mol Diagn; 2022 Jul; 24(7):784-802. PubMed ID: 35787794 [TBL] [Abstract][Full Text] [Related]
15. Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practice. Garinet S; Lupo A; Denize T; Loyaux R; Timsit S; Gazeau B; Fabre E; Maaradji Z; Gibault L; Giroux-Leprieur E; Duchemann B; Monnet I; Jouveshomme S; Aldea M; Besse B; Le Pimpec-Barthes F; Leroy K; Wislez M; Blons H Pathology; 2024 Aug; 56(5):702-709. PubMed ID: 38834439 [TBL] [Abstract][Full Text] [Related]
16. Simultaneous detection of single-nucleotide variant, deletion/insertion, and fusion in lung and thyroid carcinoma using cytology specimen and an RNA-based next-generation sequencing assay. Guseva NV; Jaber O; Stence AA; Sompallae K; Bashir A; Sompallae R; Bossler AD; Jensen CS; Ma D Cancer Cytopathol; 2018 Mar; 126(3):158-169. PubMed ID: 29364576 [TBL] [Abstract][Full Text] [Related]
17. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer. Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949 [TBL] [Abstract][Full Text] [Related]
18. Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas. Li Y; Gao L; Ma D; Qiu T; Li W; Li W; Guo L; Xing P; Liu B; Deng L; Fu J; Li J; Yu Y; Ying J Lung Cancer; 2018 Aug; 122():113-119. PubMed ID: 30032818 [TBL] [Abstract][Full Text] [Related]
19. Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay. Hou H; Yang X; Zhang J; Zhang Z; Xu X; Zhang X; Zhang C; Liu D; Yan W; Zhou N; Zhu H; Qian Z; Li Z; Zhang X Sci Rep; 2017 Nov; 7(1):14605. PubMed ID: 29097733 [TBL] [Abstract][Full Text] [Related]
20. Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung cancer. Moore DA; Benafif S; Poskitt B; Argue S; Lee SM; Ahmad T; Papadatos-Pastos D; Jamal-Hanjani M; Bennett P; Forster MD Lung Cancer; 2021 Nov; 161():55-59. PubMed ID: 34536732 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]